Valuation: Personalis, Inc.

Market Cap 1.74B 1.53B 1.45B 1.31B 2.47B 167B 2.48B 17.36B 6.7B 85.37B 6.54B 6.4B 274B P/E 2026 *
-14.9x
P/E 2027 * -17.3x
Enterprise Value 1.57B 1.38B 1.3B 1.18B 2.22B 150B 2.23B 15.59B 6.02B 76.68B 5.88B 5.75B 246B EV / Sales 2026 *
19x
EV / Sales 2027 * 15x
Free-Float
73.86%
Yield 2026 *
-
Yield 2027 * -
1 day-0.85%
1 week+0.49%
Current month-2.74%
1 month-4.39%
3 months+25.35%
6 months+157.41%
Current year+105.03%
1 week 16
Extreme 16
16.77
1 month 15.92
Extreme 15.915
17.38
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
21.69
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 2023-03-01
Chief Executive Officer 65 2022-12-30
President 55 2026-03-12
Director TitleAgeSince
Director/Board Member 79 2019-04-30
Chairman 76 2022-05-16
Director/Board Member 72 2021-03-05
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Sell

Chief Financial Officer

-2,931 0.0028%
9/18/26 Sell

Chairperson

-3,998 0.0038%
9/18/26 Sell

Chief Executive Officer

-7,459 0.0071%
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%+0.49%+170.20%+1,271.43% 1.74B
+0.43%+4.23%+12.85%+37.83% 49.06B
+0.22%+0.40%+50.91%+37.06% 44.6B
-1.58%+4.66%+359.34%+614.38% 43.24B
+1.70%+0.36%+12.56%+99.27% 41.73B
+0.51%-1.71%+5.18%+46.87% 29.93B
-0.48%-1.32%+23.98%+150.01% 17.19B
+0.08%+9.03%+8.41% - 15.35B
-1.98%-2.28%+26.91%+44.22% 15.54B
+1.97%-3.17% - - 15.11B
Average +0.00%+1.71%+74.48%+287.63% 27.35B
Weighted average by Cap. +0.14%+2.25%+78.85%+169.12%

Financials

2026 *2027 *
Net sales 82.47M 72.53M 68.59M 62.21M 117M 7.92B 118M 821M 317M 4.04B 310M 303M 12.98B 110M 96.92M 91.65M 83.13M 156M 10.58B 157M 1.1B 424M 5.4B 414M 405M 17.35B
Net income -115M -101M -95.72M -86.82M -163M -11.05B -164M -1.15B -443M -5.64B -432M -423M -18.12B -102M -89.67M -84.79M -76.91M -144M -9.79B -145M -1.02B -392M -4.99B -383M -374M -16.05B
Net Debt -178M -156M -148M -134M -252M -17.05B -253M -1.77B -683M -8.7B -667M -652M -27.95B -91.04M -80.07M -75.72M -68.67M -129M -8.74B -130M -907M -350M -4.46B -342M -334M -14.33B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
26-09-28 US$16.32 -0.85% 1,669,452
26-09-25 US$16.46 -0.66% 1,016,100
26-09-24 US$16.57 +1.35% 1,706,959
26-09-23 US$16.35 -0.06% 1,123,846
26-09-22 US$16.36 +0.74% 1,369,628
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
16.32USD
Average target price
15.44USD
Spread / Average Target
-5.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock